Optimizing mifepristone levels for cushing's patients

A method of treating hypercortisolism in a patient, with the proviso that the patient is not already suffering from a condition indicated for treatment with mifepristone, the method comprising:

• administering a daily dose of 300 milligrams per day (mg/day) of mifepristone to said patient for at least 7 days;
• then,
• if the patient's plasma mifepristone trough level is less than 2200 ng/mL, increasing the daily dose amount of mifepristone to 600 mg/day, or, continuing administration of said 300 mg daily dose of mifepristone if said plasma mifepristone trough level is equal to or greater than 2200 ng/mL;
• and,
• when said daily dose of mifepristone has been increased to 600 mg/day,
• administering said daily dose of 600 mg/day of mifepristone to said patient for at least 7 days, and then,
• if the patient's plasma mifepristone trough level is less than 2200 ng/mL, increasing the daily dose amount of mifepristone to 900 mg/day, or continuing administration of said 600 mg daily dose of mifepristone if said plasma mifepristone trough level is equal to or greater than 2200 ng/mL;
• and,
• when said daily dose of mifepristone has been increased to 900 mg/day,
• administering said daily dose of 900 mg/day of mifepristone to said patient for at least 7 days, and then,
• if the patient's plasma mifepristone trough level is less than 2200 ng/mL, increasing the daily dose amount of mifepristone to 1200 mg/day, or continuing administration of said 900 mg daily dose of mifepristone if said plasma mifepristone trough level is equal to or greater than 2200 ng/mL;
• thereby treating hypercortisolism in the patient.